Health and Me

Tanya Dutt

India Records 3,395 Active COVID-19 Cases, 26 Deaths, Kerala And Maharashtra Among Worst-Hit States

India Records 3,395 Active COVID-19 Cases, 26 Deaths, Kerala and Maharashtra Among Worst-Hit States

India is seeing a new surge in COVID-19 cases, with active cases reaching over 3,395 as of May 31 — nearly three times the number in a little over two weeks. Kerala, Maharashtra, and Delhi have turned into the biggest hotspots, even though health authorities continue to insist that severity is low. The increase, while not alarming in terms of hospitalizations, has seen India's health authorities keeping a closer watch with the identification of new Omicron subvariants and local clusters of cases.

With a sharp spike in active cases India is back on the global health radar. Though the numbers are still low compared to earlier waves, the rising trend in a number of states, along with the identification of new Omicron subvariants, is worth examining.

Also Read: <a href="https://www.healthandme.com/health-wellness/colon-cancer-is-rising-in-millennials-but-this-one-symptom-still-feels-too-embarrassing-to-talk-about-article-151765842" data-type="tilCustomLink" target="_blank">Colon Cancer Is Rising In Millennials- But This One Symptom Still Feels Too Embarrassing To Talk About</a>

India has witnessed an increase in active COVID-19 cases threefold in the last two weeks, from 1,010 on May 19 to 3,395 on May 31, with official government data. The rise is specifically prominent in Kerala, Maharashtra, and Delhi — regions that have typically been early warning signs of wider transmission trends within the country.

Kerala, which currently holds the highest number of active cases at 1,336, has seen a surge from just 430 cases reported on May 26. Maharashtra follows closely with 467 active cases, more than doubling from its 209 count just days ago. Delhi’s trajectory is also concerning, with a leap from 105 to 375 cases in the same period.

Although these figures are still small compared to the peak of the pandemic, the week-on-week surge suggests a possible first wave of transmission that is being watched closely by experts.

Also Read: <a href="https://www.healthandme.com/health-news/type-2-diabetes-and-high-blood-pressure-now-affect-1-in-8-americans-study-links-combo-to-early-death-risk-article-151766208" data-type="tilCustomLink" target="_blank">Type 2 Diabetes And High Blood Pressure Now Affect 1 In 8 Americans, Study Links Combo To Early Death Risk</a>

<h2>Covid Cases: The Current Clinical Scenario</h2>

As much as there has been an increase in case numbers, the severity of infection is still low, highlight the Indian health officials and experts. Majority of the patients are recovering under home isolation and only a few need hospitalization.

Official sources and the Indian Council of Medical Research (ICMR) indicated that there is "no cause for concern" in terms of public health emergency. ICMR Director General Dr. Rajiv Bahl provided assurances to the public, saying, "As of now, the severity is generally low. There's nothing to worry about. We should be vigilant and always be prepared."

This indicates that even as the rate of transmission could be increasing, the healthcare system is not getting strained, and the virus remains following a clinically milder pattern than in earlier waves.

Also Read: <a href="https://www.healthandme.com/health-wellness/world-no-tobacco-day-2025-how-safe-vaping-is-hooking-a-new-generation-on-nicotine-article-151761403" data-type="tilCustomLink" target="_blank">How “Safe” Vaping Is Hooking A New Generation On Nicotine?</a>

India's new COVID-19 scenario is extremely regionalized, with southern and western states witnessing initial hints of flare-ups prior to infections starting to rise in northern India.

Here's a closer examination of major states:

<strong>Kerala</strong>: From 430 cases on May 26 to 1,336 on May 31. Six fatalities have been reported.

<strong>Maharashtra</strong>: Cases went from 209 to 467; seven deaths have been reported.

<strong>Delhi</strong>: Triplication of cases, from 105 to 375, with three deaths.

<strong>Karnataka</strong>: From 47 to 234 active cases in under a week.

Tamil Nadu, Gujarat, Uttar Pradesh, West Bengal, Rajasthan, Madhya Pradesh, and Punjab have all experienced moderate increases.

These figures do not only reflect an increase in transmission but a geographical spread that crosses urban and semi-urban hubs, increasing the stakes for surveillance and containment.

Four COVID deaths in India in the past 24 hours — one in each of Delhi, Kerala, Karnataka, and Uttar Pradesh. Although deaths are still in single digits, the number of deaths in this new spike includes:

<ul><li>Kerala (6 deaths since May 26)</li><li>Maharashtra (7 deaths)</li><li>Karnataka and Delhi (3 deaths each)</li><li>Other states like Tamil Nadu, Gujarat, Rajasthan, Madhya Pradesh, and Punjab (1 death each)</li></ul>

With the present low rates of hospitalization and minimal clinical severity, these deaths are being assessed in the context of co-morbidities and age-related susceptibility.

<h2>Is Multi-Variant Spread Behind the Covid Surge In India?</h2>

Epidemiologists are particularly interested in understanding whether new variants may be fueling this latest uptick. According to the Indian SARS-CoV-2 Genomics Consortium (INSACOG), two new Omicron subvariants have been detected in India:

<strong>NB.1.8.1: </strong>Detected in Tamil Nadu in April

<strong>LF.7:</strong> Four cases detected in Gujarat in May

Globally, these variants have contributed to a rise in infections in Southeast Asian countries like Singapore, Hong Kong, and parts of China.

Still, the World Health Organization (WHO) now categorizes both NB.1.8.1 and LF.7 as "variants under monitoring" rather than "variants of concern" or "variants of interest." The WHO's current position is that:

"Based on the evidence available, the added public health risk from NB.1.8.1 is assessed as low at a global level."

The most common circulating strain in India is JN.1, with 53% of the sequenced cases, followed by BA.2 with 26%, while the rest of the 20% consists of other Omicron sublineages.

<h2>Covid-19: Surveillance and Public Health Strategy</h2>

India's response to the ongoing surge is being organized through the Integrated Disease Surveillance Programme (IDSP). The government is focusing on genomic sequencing, local containment strategies, and respiratory hygiene awareness.

Public health messaging remains on high alert but against panic. No restrictions on travel, lockdowns, or new public orders have been implemented thus far.

Dr. Bahl once again reinforced, "People do not need to take any immediate action. They should follow normal precautions. So, there is nothing special to do right now."

That means maintaining current best practices like handwashing, mask-wearing in close indoor environments, and self-isolation when symptomatic.

<h2>Covid-19: Should the World Be Concerned Now?</h2>

For the global community, India's recent development is a reminder of the unpredictable nature of the pandemic. Although the world has largely left behind COVID-19 as an emergency, localized outbreaks in densely populated areas like India can ripple outward — particularly if emerging variants start to demonstrate greater transmissibility or immune escape.

The positive news still is that vaccines continue to provide strong protection against severe illness, and India's national immunization program has maintained high coverage in adult groups. However, ongoing genomic surveillance and real-time data transparency will remain crucial to avert larger outbreaks.

India's COVID-19 surge, while of limited magnitude and clinical severity, is a multifaceted convergence of regional patterns of transmission, emerging variant sequences, and preparedness in public health. With cases being largely mild and mortality rates low, the nation's health care system is still in hand but not resting on its laurels.

In the meantime, there is no cause for global alarm. Nevertheless, India's experience should prompt health systems everywhere to remain on high alert, keep genomic surveillance going, and inform the public in a transparent manner. The virus is evolving, but so is our combined ability to deal with it.

Health Conditions A-Z

health

india covid deaths

covid-19 india update

kerala covid surge

maharashtra covid cases

delhi covid count

india active covid-19

new covid variant india

covid-19 deaths

Is It Just A Summer Cold Or The NB.1.8.1 Covid Variant? How To Tell When The Symptoms Are Nearly Identical

World’s First ‘Trojan Horse’ Blood Cancer Drug Rolled Out By NHS In England

Air India Crash May Have Triggered Flight Anxiety In Millions, Expert Shares How To Overcome Aerophobia

Health News

Common Mistakes You May Be Making While Working Out

Ways You Are Runing Your Weight Loss Journey

Beyond Fruits – How To Retain Hydration And Stay Safe In Summers

Can This Extremely Hot Weather Trigger Our Mental Health?

You Are Hurting Your Gut Health With These Habits

Avoid The Heat With These Indoor Exercises

Stay Sharp! Activities That Keep Cognitive Diseases At Bay

Protect Your Cardiovascular Health With These Heart Healthy Foods

Ways To Ease Nighttime Anxiety

Smoothie Ideas That Can Help With Weight Loss

Low Fat Foods That Are Actually Unhealthy

All Suryanamaskar Poses And How To Do Them

Do Changing Seasons Affect Your Weight?

Can Heatwave Affect Your Diet?

Heatwave To Monsoon: Health Concerns With Seasonal Changes

Standing Exercises That Help You Burn Calories

Reasons To Do Dancing As A Workout

Why Summer Fruits Are A Great Addition To Your Diet?

What Should You Avoid For Your Bladder?

Lower-Body Exercises For Strong Foundation

Healthy Drinks That Improve Your Digestion

World Tobacco Day: Unexpected Ways Smoking Can Affect You

Seasonal Mood Swings? How Weather Affects Mental Health

Is Calorie Counting Healthy? Dos And Don’ts

Heat-Related Illnesses That You Should Know

Menstrual Hygiene Day: Tips On Period Hygiene

​Add These High Protein Vegetarian Meals To Your Diet​

Top 10 Workouts That Burn Most Calorie

Makhana Season – Healthy &amp; Quick Foxnut Recipes

Monsoon Ahead – Tips On Building Rainy Season Immunity

Do You Have Prickly Heat Rash – Symptoms, Causes And Treatment

Healthy No-Cook Recipes You Can Try

How Do You Calorie Count – Numbers And Nutrients

Unexpected Signs Of Dehydration – Safety And Precaution Measures

Leg Exercises You Can Do At Home To Build Strength

Foods That Promote Skin Elasticity

Must-Do Chest Exercises You Can Try At Home

What Are The Symptoms Of JN.1 COVID-19 Strain?

Why Does Sleeping Become Harder As You Age?

High-Fiber Healthy Drinks You Should Try

India is seeing a new surge in COVID-19 cases, with active cases reaching over 3,395 as of May 31 — nearly three times the number in a little over two weeks. Kerala, Maharashtra, and Delhi have turned into the biggest hotspots, even though health authorities continue to insist that severity is low. The increase, while not alarming in terms of hospitalizations, has seen India's health authorities keeping a closer watch with the identification of new Omicron subvariants and local clusters of cases.With a sharp spike in active cases India is back on the global health radar. Though the numbers are still low compared to earlier waves, the rising trend in a number of states, along with the identification of new Omicron subvariants, is worth examining.Also Read: Colon Cancer Is Rising In Millennials- But This One Symptom Still Feels Too Embarrassing To Talk AboutIndia has witnessed an increase in active COVID-19 cases threefold in the last two weeks, from 1,010 on May 19 to 3,395 on May 31, with official government data. The rise is specifically prominent in Kerala, Maharashtra, and Delhi — regions that have typically been early warning signs of wider transmission trends within the country.Kerala, which currently holds the highest number of active cases at 1,336, has seen a surge from just 430 cases reported on May 26. Maharashtra follows closely with 467 active cases, more than doubling from its 209 count just days ago. Delhi’s trajectory is also concerning, with a leap from 105 to 375 cases in the same period.Although these figures are still small compared to the peak of the pandemic, the week-on-week surge suggests a possible first wave of transmission that is being watched closely by experts.Also Read: Type 2 Diabetes And High Blood Pressure Now Affect 1 In 8 Americans, Study Links Combo To Early Death RiskCovid Cases: The Current Clinical ScenarioAs much as there has been an increase in case numbers, the severity of infection is still low, highlight the Indian health officials and experts. Majority of the patients are recovering under home isolation and only a few need hospitalization.Official sources and the Indian Council of Medical Research (ICMR) indicated that there is "no cause for concern" in terms of public health emergency. ICMR Director General Dr. Rajiv Bahl provided assurances to the public, saying, "As of now, the severity is generally low. There's nothing to worry about. We should be vigilant and always be prepared."This indicates that even as the rate of transmission could be increasing, the healthcare system is not getting strained, and the virus remains following a clinically milder pattern than in earlier waves.Also Read: How “Safe” Vaping Is Hooking A New Generation On Nicotine?Where Covid Cases Are Rising?India's new COVID-19 scenario is extremely regionalized, with southern and western states witnessing initial hints of flare-ups prior to infections starting to rise in northern India.Here's a closer examination of major states:Kerala: From 430 cases on May 26 to 1,336 on May 31. Six fatalities have been reported.Maharashtra: Cases went from 209 to 467; seven deaths have been reported.Delhi: Triplication of cases, from 105 to 375, with three deaths.Karnataka: From 47 to 234 active cases in under a week.Tamil Nadu, Gujarat, Uttar Pradesh, West Bengal, Rajasthan, Madhya Pradesh, and Punjab have all experienced moderate increases.These figures do not only reflect an increase in transmission but a geographical spread that crosses urban and semi-urban hubs, increasing the stakes for surveillance and containment.Four COVID deaths in India in the past 24 hours — one in each of Delhi, Kerala, Karnataka, and Uttar Pradesh. Although deaths are still in single digits, the number of deaths in this new spike includes:Kerala (6 deaths since May 26)Maharashtra (7 deaths)Karnataka and Delhi (3 deaths each)Other states like Tamil Nadu, Gujarat, Rajasthan, Madhya Pradesh, and Punjab (1 death each)With the present low rates of hospitalization and minimal clinical severity, these deaths are being assessed in the context of co-morbidities and age-related susceptibility.Is Multi-Variant Spread Behind the Covid Surge In India?Epidemiologists are particularly interested in understanding whether new variants may be fueling this latest uptick. According to the Indian SARS-CoV-2 Genomics Consortium (INSACOG), two new Omicron subvariants have been detected in India:NB.1.8.1: Detected in Tamil Nadu in AprilLF.7: Four cases detected in Gujarat in MayGlobally, these variants have contributed to a rise in infections in Southeast Asian countries like Singapore, Hong Kong, and parts of China.Still, the World Health Organization (WHO) now categorizes both NB.1.8.1 and LF.7 as "variants under monitoring" rather than "variants of concern" or "variants of interest." The WHO's current position is that:"Based on the evidence available, the added public health risk from NB.1.8.1 is assessed as low at a global level."The most common circulating strain in India is JN.1, with 53% of the sequenced cases, followed by BA.2 with 26%, while the rest of the 20% consists of other Omicron sublineages.Covid-19: Surveillance and Public Health StrategyIndia's response to the ongoing surge is being organized through the Integrated Disease Surveillance Programme (IDSP). The government is focusing on genomic sequencing, local containment strategies, and respiratory hygiene awareness.Public health messaging remains on high alert but against panic. No restrictions on travel, lockdowns, or new public orders have been implemented thus far.Dr. Bahl once again reinforced, "People do not need to take any immediate action. They should follow normal precautions. So, there is nothing special to do right now."That means maintaining current best practices like handwashing, mask-wearing in close indoor environments, and self-isolation when symptomatic.Covid-19: Should the World Be Concerned Now?For the global community, India's recent development is a reminder of the unpredictable nature of the pandemic. Although the world has largely left behind COVID-19 as an emergency, localized outbreaks in densely populated areas like India can ripple outward — particularly if emerging variants start to demonstrate greater transmissibility or immune escape.The positive news still is that vaccines continue to provide strong protection against severe illness, and India's national immunization program has maintained high coverage in adult groups. However, ongoing genomic surveillance and real-time data transparency will remain crucial to avert larger outbreaks.India's COVID-19 surge, while of limited magnitude and clinical severity, is a multifaceted convergence of regional patterns of transmission, emerging variant sequences, and preparedness in public health. With cases being largely mild and mortality rates low, the nation's health care system is still in hand but not resting on its laurels.In the meantime, there is no cause for global alarm. Nevertheless, India's experience should prompt health systems everywhere to remain on high alert, keep genomic surveillance going, and inform the public in a transparent manner. The virus is evolving, but so is our combined ability to deal with it.

india records 3,395 active covid-19 cases, 26 deaths, kerala and maharashtra among worst-hit states

New Once-a-Week Pill May Transform Schizophrenia Treatment, Lancet Study Finds

new once-a-week pill may transform schizophrenia treatment, lancet study finds

Health & Wellness

Can You Get Cervical Cancer Without HPV?

can you get cervical cancer without hpv?

Smartphone Tool Can Now Detect Early Warning Signs Of Huntington’s Disease In 5 Minutes, Finds Study

smartphone tool can now detect early warning signs of huntington’s disease in 5 minutes, finds study

Blood Tests Could Reveal Cancer Cells 3 Years Before The Actual Diagnosis

blood tests could reveal cancer cells 3 years before the actual diagnosis

The England National Health Service (NHS) is the world's first healthcare system to offer a revolutionary <span>blood cancer</span> treatment called a "Trojan horse" drug. The trailblazing treatment, officially known as <span>belantamab mafodotin</span>, has the potential to add years to the lives of thousands of patients fighting multiple myeloma, a vicious and currently untreatable form of bone marrow cancer.

This innovation, now being rolled out to eligible patients throughout England, highlights the revolutionary promise of precision medicine and targeted treatments to change cancer care.

At the center of this medical innovation is belantamab mafodotin, also known as Blenrep and produced by GlaxoSmithKline. In contrast to traditional chemotherapy that gets into both healthy and cancer cells, this new medication uses a targeted approach: it binds to myeloma cells, enters them quietly, and delivers a fatal dose of chemotherapy directly within, effectively killing the malignancy from the inside out.

This "Trojan horse" metaphor comes from Greek mythology, as Greek warriors entered the city of Troy disguised within a wooden horse. In the same way, this drug corrupts cancer cells by smuggling a toxic payload into them disguised as an antibody—spared most healthy tissues in the process.

NHS England National Clinical Director for Cancer Professor Peter Johnson called the treatment "life-changing" and said, "Myeloma is an aggressive blood cancer, but the advent of belantamab mafodotin brings with it a new hope of highly extended disease control.

Multiple myeloma is a plasma cancer that arises in plasma cells present in the bone marrow. Although there are continued advances in medicine, the disease is still incurable and relapsing in nature. The majority of patients have a pattern of recurrence after remission, requiring multiple treatment lines.

Trials of belantamab mafodotin, particularly in combination with other drugs such as bortezomib and dexamethasone, have shown that the treatment can stop disease from progressing for a period of three years—three years longer than the 13-month postponement achieved with the drug of choice at present, daratumumab.

The National Institute for Health and Care Excellence (NICE), having checked the effectiveness and value for money, accelerated approval for the rollout of the treatment. NICE director Helen Knight stated, "This recommendation shows our determination to get patients the best treatment quickly while protecting value for the taxpayer." 

The NHS rollout will first address about 1,500 patients per year in England that have relapsed or are resistant to their existing treatments. These are often those with advanced myeloma who have run out of other standard treatments.

Significantly, this represents a move toward personalized, next-generation treatments being accessible through public healthcare facilities—an accomplishment welcomed by health activists and oncologists alike.

Shelagh McKinlay, Myeloma UK's Director of Research and Advocacy, hailed the announcement: "We have campaigned aggressively for the last year to get this drug approved. It will change the lives of thousands of myeloma patients."

Paul Silvester, who is 60 and from Sheffield, was diagnosed with multiple myeloma in 2023. When ordinary treatment and even a bone marrow transplant did not halt the disease, he was put on an early-access trial for belantamab mafodotin at the Royal Hallamshire Hospital.

The change was almost instant," he explained. "In the first two or three weeks following the first dose, I was in remission. I like to think this treatment has brought the party balloons into the house."

Paul is now in remission and mapping out history-themed travel excursions—something he never thought he'd ever be able to do a few months ago.

<h2>How Does Belantamab Mafodotin Work?</h2>

Belantamab mafodotin is an antibody-drug conjugate (ADC), a new class of cancer drugs. The drug's antibody component targets a protein (BCMA) on the outside of myeloma cells. After binding to the cancer cell, the complex is taken into the cell where it drops off a potent chemotherapy drug, essentially killing it from within.

This internal targeting results in much less collateral damage to normal cells—a major problem with standard chemotherapy—and decreases the overall treatment burden.

Although thought to be less toxic than many standard therapies, belantamab mafodotin is not without adverse effects. Patients can have dry eyes, blurred vision, and occasionally more severe ocular toxicity due to the mechanism of action of the drug leaking into surrounding tissues after cell kill.

Clinical teams are trained to monitor and manage these effects, often adjusting dosage or incorporating supportive therapies to preserve patient safety.

Health Minister Karin Smyth emphasized the significance of this development: “This groundbreaking therapy puts the NHS at the forefront of cancer innovation. By harnessing cutting-edge ‘Trojan horse’ technology, we’re offering new hope to blood cancer patients across the country.”

In fact, the move by the NHS to be the first healthcare system in the world to introduce this treatment establishes a precedent for the incorporation of high-cost, high-impact biologic therapies into national care.

With its effective implementation in England, belantamab mafodotin could soon be used as a worldwide standard of care for relapsed or refractory multiple myeloma. As other nations observe outcomes and cost-effectiveness trends, it is possible that health systems globally will look into implementing this Trojan horse technique.

Researchers in oncology are also looking at similar antibody-drug conjugates for other types of cancer, including breast, lung, and ovarian cancers—implying that we are just beginning to see what this technology has to give.

blood cancer

trojan horse cancer drug

belantamab mafodotin

multiple myeloma treatment

nhs blood cancer therapy

blenrep approval uk

antibody drug for myeloma

blood cancer breakthrough

The England National Health Service (NHS) is the world's first healthcare system to offer a revolutionary blood cancer treatment called a "Trojan horse" drug. The trailblazing treatment, officially known as belantamab mafodotin, has the potential to add years to the lives of thousands of patients fighting multiple myeloma, a vicious and currently untreatable form of bone marrow cancer.This innovation, now being rolled out to eligible patients throughout England, highlights the revolutionary promise of precision medicine and targeted treatments to change cancer care.How Does This Therapy Work?At the center of this medical innovation is belantamab mafodotin, also known as Blenrep and produced by GlaxoSmithKline. In contrast to traditional chemotherapy that gets into both healthy and cancer cells, this new medication uses a targeted approach: it binds to myeloma cells, enters them quietly, and delivers a fatal dose of chemotherapy directly within, effectively killing the malignancy from the inside out.This "Trojan horse" metaphor comes from Greek mythology, as Greek warriors entered the city of Troy disguised within a wooden horse. In the same way, this drug corrupts cancer cells by smuggling a toxic payload into them disguised as an antibody—spared most healthy tissues in the process.NHS England National Clinical Director for Cancer Professor Peter Johnson called the treatment "life-changing" and said, "Myeloma is an aggressive blood cancer, but the advent of belantamab mafodotin brings with it a new hope of highly extended disease control.Multiple myeloma is a plasma cancer that arises in plasma cells present in the bone marrow. Although there are continued advances in medicine, the disease is still incurable and relapsing in nature. The majority of patients have a pattern of recurrence after remission, requiring multiple treatment lines.Trials of belantamab mafodotin, particularly in combination with other drugs such as bortezomib and dexamethasone, have shown that the treatment can stop disease from progressing for a period of three years—three years longer than the 13-month postponement achieved with the drug of choice at present, daratumumab.The National Institute for Health and Care Excellence (NICE), having checked the effectiveness and value for money, accelerated approval for the rollout of the treatment. NICE director Helen Knight stated, "This recommendation shows our determination to get patients the best treatment quickly while protecting value for the taxpayer." Who Will Benefit?The NHS rollout will first address about 1,500 patients per year in England that have relapsed or are resistant to their existing treatments. These are often those with advanced myeloma who have run out of other standard treatments.Significantly, this represents a move toward personalized, next-generation treatments being accessible through public healthcare facilities—an accomplishment welcomed by health activists and oncologists alike.Shelagh McKinlay, Myeloma UK's Director of Research and Advocacy, hailed the announcement: "We have campaigned aggressively for the last year to get this drug approved. It will change the lives of thousands of myeloma patients."Paul Silvester, who is 60 and from Sheffield, was diagnosed with multiple myeloma in 2023. When ordinary treatment and even a bone marrow transplant did not halt the disease, he was put on an early-access trial for belantamab mafodotin at the Royal Hallamshire Hospital.The change was almost instant," he explained. "In the first two or three weeks following the first dose, I was in remission. I like to think this treatment has brought the party balloons into the house."Paul is now in remission and mapping out history-themed travel excursions—something he never thought he'd ever be able to do a few months ago.How Does Belantamab Mafodotin Work?Belantamab mafodotin is an antibody-drug conjugate (ADC), a new class of cancer drugs. The drug's antibody component targets a protein (BCMA) on the outside of myeloma cells. After binding to the cancer cell, the complex is taken into the cell where it drops off a potent chemotherapy drug, essentially killing it from within.This internal targeting results in much less collateral damage to normal cells—a major problem with standard chemotherapy—and decreases the overall treatment burden.Side Effects and Safety IssuesAlthough thought to be less toxic than many standard therapies, belantamab mafodotin is not without adverse effects. Patients can have dry eyes, blurred vision, and occasionally more severe ocular toxicity due to the mechanism of action of the drug leaking into surrounding tissues after cell kill.Clinical teams are trained to monitor and manage these effects, often adjusting dosage or incorporating supportive therapies to preserve patient safety.Health Minister Karin Smyth emphasized the significance of this development: “This groundbreaking therapy puts the NHS at the forefront of cancer innovation. By harnessing cutting-edge ‘Trojan horse’ technology, we’re offering new hope to blood cancer patients across the country.”In fact, the move by the NHS to be the first healthcare system in the world to introduce this treatment establishes a precedent for the incorporation of high-cost, high-impact biologic therapies into national care.With its effective implementation in England, belantamab mafodotin could soon be used as a worldwide standard of care for relapsed or refractory multiple myeloma. As other nations observe outcomes and cost-effectiveness trends, it is possible that health systems globally will look into implementing this Trojan horse technique.Researchers in oncology are also looking at similar antibody-drug conjugates for other types of cancer, including breast, lung, and ovarian cancers—implying that we are just beginning to see what this technology has to give.

world’s first ‘trojan horse’ blood cancer drug rolled out by nhs in england

Ishita Roy

RFK Hires Autism Skeptic To Look Into CDC Autism Data

RFK Hires Autism Skeptic

Kennedy Names New Vaccine Advisers Among Whom Are Anti-Vaxxers And Those Who Spread Misinformation

kennedy names new vaccine advisers among whom are anti-vaxxers and those who spread misinformation. after ousting the entire panel

Worried About The New And Dominant COVID Variant XEC? 3 Things You Must Know

worried about the new and dominant covid variant xec? 3 things you must know

COVID NB.1.8.1 Variant Triggers Extreme Throat Pain That Feels Like Swallowing 'Razor Blades'

covid nb.1.8.1 variant triggers extreme throat pain that feels like swallowing 'razor blades

is it just a summer cold or the nb.1.8.1 covid variant? how to tell when the symptoms are nearly identical

Dr. David Geier, a controversial orthopedic surgeon and known vaccine skeptic, is attempting to revisit long-debunked claims linking vaccines to autism. Recently hired by Health Secretary Robert F. Kennedy Jr., Geier is now reviewing historical safety data to investigate whether government agencies concealed crucial information.

<h4>Accessing <span rel="noindex">CDC</span>'s Vaccine Safety Database</h4>

Geier is reportedly seeking access to the U.S. Centers for Disease Control and Prevention’s (CDC) Vaccine Safety Datalink (VSD), a repository of vaccine safety records from millions of patients. The VSD is maintained by a dozen major healthcare systems, each controlling its own data. Full access has always been tightly controlled due to privacy and misuse concerns.

Geier previously accessed the database in 2004 and 2006. However, according to The Wall Street Journal, CDC officials revoked his access both times, alleging he had misrepresented his research intentions.

Despite this, Geier is once again pushing to analyze the data. It remains unclear if access has been granted. A spokesperson for the U.S. Department of Health and Human Services (HHS) stated that the department intends to take a “fresh look at all data including old data,” and emphasized that they would “follow the science—wherever it leads.”

<h4>Scientific Community Raises Concerns</h4>

The scientific and public health communities have expressed concern over Geier's involvement. “He has no record in the scientific community of doing valid work,” said Dr. Walter Orenstein, former director of the CDC’s immunization program.

Geier and his late father, geneticist Mark Geier, have long promoted the theory that vaccines cause autism—an idea widely discredited by the medical community. The pair also introduced a controversial treatment using hormone-blocking drugs, which resulted in the revocation of Mark Geier’s medical license and disciplinary actions against David Geier for practicing medicine without a license.

At a 2015 conference, Geier defended his position, claiming the scientific community dismisses their findings without proper consideration. “They think that [the vaccine's link to autism has] been completely debunked,” he said at the time.

<h4>Kennedy's Role and the Larger Context</h4>

Robert F. Kennedy Jr., a vocal critic of vaccine mandates, has clarified that Geier will not lead autism research. Instead, his focus will be on identifying any possibly overlooked or hidden data within the CDC’s database.

“There has been a lot of monkey business with the VSD,” Kennedy stated in a previous congressional appearance.

Kennedy, who once authored a now-retracted Rolling Stone article alleging a vaccine-autism cover-up, cited a 2000 CDC conference that explored preliminary data on thimerosal—a mercury-based preservative once used in vaccines. Though early findings prompted questions, later analysis confirmed no link between thimerosal and autism. Thimerosal was removed from most vaccines in 2001, and final results were published in 2003.

<h4>Exploring Autism Causes and Rising Rates</h4>

While Geier conducts his review, the U.S. Department of Health and Human Services is separately examining rising autism rates. The CDC now estimates that 1 in 31 eight-year-olds in the U.S. were diagnosed with autism in 2022. Experts attribute the increase to a combination of better diagnostic methods, genetic factors, and increased awareness.

The National Institutes of Health (NIH) also plans to fund research into other possible causes, such as environmental toxins and diet. Meanwhile, Children's Health Defense, a nonprofit formerly led by Kennedy, is hosting an online event this week centered on what it calls the “autism cover-up.”

us health news

health news

vaccines and autism

rfk hires autism critic

Dr. David Geier, a controversial orthopedic surgeon and known vaccine skeptic, is attempting to revisit long-debunked claims linking vaccines to autism. Recently hired by Health Secretary Robert F. Kennedy Jr., Geier is now reviewing historical safety data to investigate whether government agencies concealed crucial information.Accessing CDC's Vaccine Safety DatabaseGeier is reportedly seeking access to the U.S. Centers for Disease Control and Prevention’s (CDC) Vaccine Safety Datalink (VSD), a repository of vaccine safety records from millions of patients. The VSD is maintained by a dozen major healthcare systems, each controlling its own data. Full access has always been tightly controlled due to privacy and misuse concerns.Geier previously accessed the database in 2004 and 2006. However, according to The Wall Street Journal, CDC officials revoked his access both times, alleging he had misrepresented his research intentions.Despite this, Geier is once again pushing to analyze the data. It remains unclear if access has been granted. A spokesperson for the U.S. Department of Health and Human Services (HHS) stated that the department intends to take a “fresh look at all data including old data,” and emphasized that they would “follow the science—wherever it leads.”Scientific Community Raises ConcernsThe scientific and public health communities have expressed concern over Geier's involvement. “He has no record in the scientific community of doing valid work,” said Dr. Walter Orenstein, former director of the CDC’s immunization program.Geier and his late father, geneticist Mark Geier, have long promoted the theory that vaccines cause autism—an idea widely discredited by the medical community. The pair also introduced a controversial treatment using hormone-blocking drugs, which resulted in the revocation of Mark Geier’s medical license and disciplinary actions against David Geier for practicing medicine without a license.At a 2015 conference, Geier defended his position, claiming the scientific community dismisses their findings without proper consideration. “They think that [the vaccine's link to autism has] been completely debunked,” he said at the time.Kennedy's Role and the Larger ContextRobert F. Kennedy Jr., a vocal critic of vaccine mandates, has clarified that Geier will not lead autism research. Instead, his focus will be on identifying any possibly overlooked or hidden data within the CDC’s database.“There has been a lot of monkey business with the VSD,” Kennedy stated in a previous congressional appearance.Kennedy, who once authored a now-retracted Rolling Stone article alleging a vaccine-autism cover-up, cited a 2000 CDC conference that explored preliminary data on thimerosal—a mercury-based preservative once used in vaccines. Though early findings prompted questions, later analysis confirmed no link between thimerosal and autism. Thimerosal was removed from most vaccines in 2001, and final results were published in 2003.Exploring Autism Causes and Rising RatesWhile Geier conducts his review, the U.S. Department of Health and Human Services is separately examining rising autism rates. The CDC now estimates that 1 in 31 eight-year-olds in the U.S. were diagnosed with autism in 2022. Experts attribute the increase to a combination of better diagnostic methods, genetic factors, and increased awareness.The National Institutes of Health (NIH) also plans to fund research into other possible causes, such as environmental toxins and diet. Meanwhile, Children's Health Defense, a nonprofit formerly led by Kennedy, is hosting an online event this week centered on what it calls the “autism cover-up.”

rfk hires autism skeptic to look into cdc autism data

Covid-19 Active Cases Cross 7,100 In India But Signs Point To A Slowdown—How To Stay Protected Now?

India's COVID Tally Soars To Nearly 7000 Active Cases With 3 Deaths In 24 Hours; Is A New Wave Here?

india's covid tally soars to nearly 7000 active cases with 3 deaths in 24 hours; is a new wave here?

India is again facing a concerning but seemingly controlled increase in <span>Covid-19</span> cases. As of June 13, 2025, the active case count of the country is 7,131, as per the Ministry of Health and Family Welfare. Although new daily cases increased by 33 and three more deaths were added—two in Maharashtra and one in Madhya Pradesh—the overall trend indicates a potential plateau and even a slight dip, which gives optimistic hopes.

The most recent state-by-state Covid-19 dashboard published by the Ministry of Health and Family Welfare indicates remarkable regional variations in infection incidence in India. Kerala remains to have the highest burden, with 2,055 active cases, out of which 110 were new cases in one day. Gujarat is the second worst-affected state with 1,358 active cases, which saw a steep daily jump of 77 cases. Other majorly affected states are West Bengal, with 747 active cases; Delhi, with 714 cases; and Maharashtra, with 629 active infections. The Karnataka region showed a significant increase with 72 new cases, taking its active caseload to 395. On the other hand, there are no active Covid-19 cases in certain states like Arunachal Pradesh, Mizoram, and Manipur, hinting at effective containment measures. In spite of these diverse regional numbers, the overall national trend seems positively tentative. There were 1,420 new recoveries logged, elevating the total number of recovered or migrated persons to 10,976 for the year, which highlights India's resilience in its continuous Covid-19 response.

The increase is credited mainly to new Omicron sub-variants, such as JN.1, LF.7, NB.1.8.1, and XFG, which are highly contagious but produce milder symptoms than previous strains. These variants are now listed as "Variants Under Monitoring" by the World Health Organization (WHO). While not yet classified as variants of concern, they necessitate heightened vigilance, particularly among high-risk groups.

Experts advise against attributing these numbers to the onset of a full-blown wave. Rather, they refer to a seasonal surge, similar to the flu, which is consonant with the virus's post-pandemic shift towards an endemic pattern.

<h2>Why Are Booster Shots Not Recommended?</h2>

In light of India's high hybrid immunity from both vaccinations and past infections, health authorities as of now not recommending mass booster drives. Rather, targeted vaccination is being encouraged for:

<ul><li>The elderly</li><li>Immunocompromised hosts</li><li>People with chronic respiratory or cardiovascular disease</li></ul>

The Indian Medical Association and health professionals emphasize that this risk-based, strategic strategy is more effective protection than mass immunization campaigns.

Even with the recent upsurge, health workers urge not panicking but remaining proactive. Distinguishing between Covid-19 and other common seasonal viral infections—often producing the same symptoms as fever, fatigue, and cough—is now of paramount importance.

Physicians and public health specialist, point out that exhaustion from sustained lookout can precipitate complacency. We can't ignore Covid-19 as a historical moment. It's very much still around—but controlled with the appropriate preventive measures.

<h2>Actionable Tips To Prevent COVID Infection</h2>

Nowadays, personal responsibility and daily routine are still your best protection. Here's how to protect yourself:

<h4>1. Wear a Mask in Crowded Indoor Spaces</h4>

Though mandates may have disappeared, masks are effective, especially in poorly ventilated spaces indoors, on public transportation, and in medical offices.

<h4>2. Get Current with Targeted Vaccines</h4>

If you are in a high-risk group, speak with your health care provider about boosters that are available or trials soon to be under way for new variant-specific vaccines.

Prioritize a balanced diet, proper sleep, and regular physical activity in order to maintain your immune system strong against not only Covid-19 but also other flu and seasonal diseases.

Good hygiene habits such as regular handwashing, the use of sanitizers, and not touching your face while in public can significantly minimize the risk of transmission.

If you are symptomatic—or have someone living with you who is—skip gatherings and go remote work whenever possible.

Notice signs such as fever, chronic cough, body pain, fatigue, and taste/smell loss. Test early and self-isolate to avoid transmission.

Particularly if above 60 years or with underlying conditions, don't wait even for minor symptoms. Early treatment can be life-saving.

The India Covid-19 situation is serious but under control. Yes, the active cases are more than 7,100, but the recovery rates are robust, and the fatalities are few and limited to the vulnerable groups.

Instead of fear, this time it requires a recommitment to public health practices—from mask-wearing when necessary to symptom-watching and protecting the vulnerable.

India is again facing a concerning but seemingly controlled increase in Covid-19 cases. As of June 13, 2025, the active case count of the country is 7,131, as per the Ministry of Health and Family Welfare. Although new daily cases increased by 33 and three more deaths were added—two in Maharashtra and one in Madhya Pradesh—the overall trend indicates a potential plateau and even a slight dip, which gives optimistic hopes.The most recent state-by-state Covid-19 dashboard published by the Ministry of Health and Family Welfare indicates remarkable regional variations in infection incidence in India. Kerala remains to have the highest burden, with 2,055 active cases, out of which 110 were new cases in one day. Gujarat is the second worst-affected state with 1,358 active cases, which saw a steep daily jump of 77 cases. Other majorly affected states are West Bengal, with 747 active cases; Delhi, with 714 cases; and Maharashtra, with 629 active infections. The Karnataka region showed a significant increase with 72 new cases, taking its active caseload to 395. On the other hand, there are no active Covid-19 cases in certain states like Arunachal Pradesh, Mizoram, and Manipur, hinting at effective containment measures. In spite of these diverse regional numbers, the overall national trend seems positively tentative. There were 1,420 new recoveries logged, elevating the total number of recovered or migrated persons to 10,976 for the year, which highlights India's resilience in its continuous Covid-19 response.The increase is credited mainly to new Omicron sub-variants, such as JN.1, LF.7, NB.1.8.1, and XFG, which are highly contagious but produce milder symptoms than previous strains. These variants are now listed as "Variants Under Monitoring" by the World Health Organization (WHO). While not yet classified as variants of concern, they necessitate heightened vigilance, particularly among high-risk groups.Experts advise against attributing these numbers to the onset of a full-blown wave. Rather, they refer to a seasonal surge, similar to the flu, which is consonant with the virus's post-pandemic shift towards an endemic pattern.Why Are Booster Shots Not Recommended?In light of India's high hybrid immunity from both vaccinations and past infections, health authorities as of now not recommending mass booster drives. Rather, targeted vaccination is being encouraged for:The elderlyImmunocompromised hostsPeople with chronic respiratory or cardiovascular diseaseThe Indian Medical Association and health professionals emphasize that this risk-based, strategic strategy is more effective protection than mass immunization campaigns.Even with the recent upsurge, health workers urge not panicking but remaining proactive. Distinguishing between Covid-19 and other common seasonal viral infections—often producing the same symptoms as fever, fatigue, and cough—is now of paramount importance.Physicians and public health specialist, point out that exhaustion from sustained lookout can precipitate complacency. We can't ignore Covid-19 as a historical moment. It's very much still around—but controlled with the appropriate preventive measures.Actionable Tips To Prevent COVID InfectionNowadays, personal responsibility and daily routine are still your best protection. Here's how to protect yourself:1. Wear a Mask in Crowded Indoor SpacesThough mandates may have disappeared, masks are effective, especially in poorly ventilated spaces indoors, on public transportation, and in medical offices.2. Get Current with Targeted VaccinesIf you are in a high-risk group, speak with your health care provider about boosters that are available or trials soon to be under way for new variant-specific vaccines.3. Boost Your Immune SystemPrioritize a balanced diet, proper sleep, and regular physical activity in order to maintain your immune system strong against not only Covid-19 but also other flu and seasonal diseases.4. Practice HygieneGood hygiene habits such as regular handwashing, the use of sanitizers, and not touching your face while in public can significantly minimize the risk of transmission.5. Stay Away from CrowdsIf you are symptomatic—or have someone living with you who is—skip gatherings and go remote work whenever possible.6. Identify Symptoms EarlyNotice signs such as fever, chronic cough, body pain, fatigue, and taste/smell loss. Test early and self-isolate to avoid transmission.7. Seek Medical HelpParticularly if above 60 years or with underlying conditions, don't wait even for minor symptoms. Early treatment can be life-saving.The India Covid-19 situation is serious but under control. Yes, the active cases are more than 7,100, but the recovery rates are robust, and the fatalities are few and limited to the vulnerable groups.Instead of fear, this time it requires a recommitment to public health practices—from mask-wearing when necessary to symptom-watching and protecting the vulnerable.Key Figures at a Glance (as of June 13, 2025)Total Active Cases: 7,131New Cases in 24 Hours: 33Total Deaths (2025): 78Top States by Active Cases: Kerala (2055), Gujarat (1358), West Bengal (747), Delhi (714), Maharashtra (629)Recovered in 2025: 10,976 and risingDeath IN Last 24 Hours: 1 (Kerala)

India Records 3,395 Active COVID-19 Cases, 26 Deaths, Kerala And Maharashtra Among Worst-Hit States

Quick Stories

World’s First ‘Trojan Horse’ Blood Cancer Drug Rolled Out By NHS In England

RFK Hires Autism Skeptic To Look Into CDC Autism Data

Covid-19 Active Cases Cross 7,100 In India But Signs Point To A Slowdown—How To Stay Protected Now?

Health Conditions A-Z

Is It Just A Summer Cold Or The NB.1.8.1 Covid Variant? How To Tell When The Symptoms Are Nearly Identical

World’s First ‘Trojan Horse’ Blood Cancer Drug Rolled Out By NHS In England

Air India Crash May Have Triggered Flight Anxiety In Millions, Expert Shares How To Overcome Aerophobia